Emcure Pharmaceuticals reported a 36.2% rise in net profit to ₹292.5 crore for the June quarter, supported by a 22.8% increase in revenue. The growth was largely driven by a strong 34.2% performance in its international business segment. The company also announced a leadership transition, with current CEO Satish Mehta set to become Chairman.
Emcure Pharmaceuticals released its financial results for the first quarter of the 2026-27 fiscal year on Thursday, reporting a 36.2% increase in consolidated net profit to ₹292.5 crore. The company’s revenue from operations also saw a healthy rise, climbing 22.8% to ₹2,580.4 crore compared to the same period last year.
The primary driver of this growth has been the company’s international business, which expanded by 34.2% to ₹1,485.1 crore. This segment is now a significant part of the company's business, accounting for 58% of total revenue. In contrast, the domestic market showed steady growth of 10.2%, contributing ₹1,095.3 crore to the total topline.
On the operational side, the company reported an EBITDA of ₹508 crore, reflecting a 25.8% increase, while its EBITDA margin improved to 19.7%. Investors may note the company's focus on maintaining a healthy balance sheet, with its net debt-to-EBITDA ratio standing at a low 0.6x as of June 30, 2026. This indicates that the company is currently using debt conservatively relative to its operating earnings.
Alongside the financial results, the company announced a shift in its leadership structure. Chairman Berjis Desai is set to retire at the upcoming Annual General Meeting. Following this, the current Managing Director and CEO, Satish Mehta, will take on the role of Chairman. The company also appointed Raghu Kumar as an additional independent director, effective today.
Looking ahead, investors may track how the company manages the risks inherent in its large international portfolio. Since 58% of revenue comes from abroad, fluctuations in currency exchange rates can impact earnings. Additionally, the pharmaceutical sector remains exposed to regulatory hurdles, such as the approval of new drugs and evolving compliance standards in global markets. The company’s ability to manage raw material price volatility while maintaining its profit margins will also be important to watch in the coming quarters.